119 related articles for article (PubMed ID: 36718661)
21. Stathmin guides personalized therapy in oral squamous cell carcinoma.
Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
[TBL] [Abstract][Full Text] [Related]
22. Autophagy Induced by Areca Nut Extract Contributes to Decreasing Cisplatin Toxicity in Oral Squamous Cell Carcinoma Cells: Roles of Reactive Oxygen Species/AMPK Signaling.
Xu Z; Huang CM; Shao Z; Zhao XP; Wang M; Yan TL; Zhou XC; Jiang EH; Liu K; Shang ZJ
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257034
[TBL] [Abstract][Full Text] [Related]
23. NEDD4L inhibits glycolysis and proliferation of cancer cells in oral squamous cell carcinoma by inducing ENO1 ubiquitination and degradation.
Zhang G; Zhao X; Liu W
Cancer Biol Ther; 2022 Dec; 23(1):243-253. PubMed ID: 35316145
[TBL] [Abstract][Full Text] [Related]
24. Sensitization of colon cancer cells to cisplatin by Fbxw7 via negative regulation of the Nox1-mTOR pathway.
Huang G; Long K
Pathol Res Pract; 2023 Jul; 247():154479. PubMed ID: 37262995
[TBL] [Abstract][Full Text] [Related]
25. San-Zhong-Kui-Jian-Tang Exerts Antitumor Effects Associated With Decreased Cell Proliferation and Metastasis by Targeting ERK and the Epithelial-Mesenchymal Transition Pathway in Oral Cavity Squamous Cell Carcinoma.
Hsu PY; Chen JL; Kuo SL; Wang WL; Jan FW; Yang SH; Yang CY
Integr Cancer Ther; 2022; 21():15347354221134921. PubMed ID: 36404765
[TBL] [Abstract][Full Text] [Related]
26. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
[TBL] [Abstract][Full Text] [Related]
27. Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway.
Feng Y; Cao X; Zhao B; Song C; Pang B; Hu L; Zhang C; Wang J; He J; Wang S
Sci China Life Sci; 2021 Nov; 64(11):1814-1828. PubMed ID: 34542810
[TBL] [Abstract][Full Text] [Related]
28. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
29. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
Ren J
Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
[TBL] [Abstract][Full Text] [Related]
30. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.
Zhu H; Wu J; Zhang W; Luo H; Shen Z; Cheng H; Zhu X
Sci Rep; 2016 Aug; 6():30788. PubMed ID: 27492148
[TBL] [Abstract][Full Text] [Related]
31. Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells.
Zainal NS; Gan CP; Lau BF; Yee PS; Tiong KH; Abdul Rahman ZA; Patel V; Cheong SC
Phytomedicine; 2018 Jan; 39():33-41. PubMed ID: 29433681
[TBL] [Abstract][Full Text] [Related]
32. FOXD1-mTOR Signaling Pathway on Oral Squamous Cell Carcinoma and Its Inhibition by Rosemary Extract (Invitro-Study).
Alaa El-Din Y; Sabry D; H Ahmed S; Mohamed A
Asian Pac J Cancer Prev; 2022 Sep; 23(9):3071-3081. PubMed ID: 36172670
[TBL] [Abstract][Full Text] [Related]
33. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.
Chen L; Zhu Q; Lu L; Liu Y
Bioengineered; 2020 Dec; 11(1):91-102. PubMed ID: 31906769
[TBL] [Abstract][Full Text] [Related]
34. Metformin inhibits mTOR and c-Myc by decreasing YAP protein expression in OSCC cells.
Wang Y; Zhang Y; Feng X; Tian H; Fu X; Gu W; Wen Y
Oncol Rep; 2021 Mar; 45(3):1249-1260. PubMed ID: 33650651
[TBL] [Abstract][Full Text] [Related]
35. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
36. Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells.
Han L; Li L; Wu G
Mol Cell Probes; 2022 Aug; 64():101821. PubMed ID: 35490795
[TBL] [Abstract][Full Text] [Related]
37. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2.
Zhang K; Zhang M; Jiang H; Liu F; Liu H; Li Y
Biomed Pharmacother; 2018 Sep; 105():545-552. PubMed ID: 29886375
[TBL] [Abstract][Full Text] [Related]
39. GAS5 alleviates cisplatin drug resistance in oral squamous cell carcinoma by sponging miR-196a.
Yuan X; Jing Y; Guang M; Zhu J; Wang J; Wang Y; Zhang Y
J Int Med Res; 2022 Oct; 50(10):3000605221132456. PubMed ID: 36310502
[TBL] [Abstract][Full Text] [Related]
40. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
Lu M; Wang C; Chen W; Mao C; Wang J
DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
